- Equities: Most major global stock markets continue to post record highs boosted by the Fed’s dovish tilt and a stronger than expected economy. However, China and Hong Kong markets were lacklustre due to weakness in China’s property market.
- Credit: Diminishing demand and higher supply of US debt could lead to rising term premium and steeper yield curves, reaffirming our strategy to stay short-duration, preferring 3-5Y duration bucket
- FX: USD/JPY rose despite the end of BOJ’s negative interest rate policy and YCC framework; however, USD/JPY backed off whenever it neared 152
- Rates: Resurgence of sticky inflation pushed bond yields higher; 2Y yields hit above 4.70% and set a new high for the year
- The Week Ahead: Despite divergences amongst central banks, the broad picture of G10 easing (with exception of Japan) remains broadly intact
相關見解
- 美國大選增添匯市波動性22 Jul 2024
- 美國總統選舉對股市的影響22 Jul 2024
- Economics Weekly: Fed Easing on the Card19 Jul 2024
Global equity markets powered higher. The Dow Jones, the S&P 500 and the NASDAQ rose 2.0%, 2.3% and 2.9% respectively for the week, making new highs. A dovish Fed and better- than- expected economic data fueled gains for the US markets. Powell’s dovish tilt and comments that there are no cracks in US’ strong jobs growth boosted market sentiment. US markets registered their best week in 2024. European stock markets benefited from the Fed’s dovish tilt and the eurozone composite PMI rising to 49.9 from 49.2 in February. The STOXX 600 rose 1.0% for the week, near its record high. The Bank of Japan (BOJ) ended Japan’s negative interest rates policy (NIRP), removing an overhang on the markets. Nikkei 225 rallied 5.6% this week. In stark contrast, China and Hong Kong markets declined as China’s property sector sales continue to be weak, dropping 20% in January and March. The Shanghai Composite Index edged down 0.2% while the HSCEI and HSI dropped 1.1% and 1.3% respectively for the week.
Topic in Focus: Healthcare – Pharma’s latest blockbusters. Since receiving FDA approval for chronic weight management, weight loss drugs such as Tirzepatide and Wegovy from Eli Lilly and Novo Nordisk have been met with record demand. The insatiable demand for these weight loss drugs has propelled Novo Nordisk to beat LVMH, becoming Europe's largest company by market capitalization. YTD the makers of weight loss drugs have outperformed S&P 500 by a staggering c.20%.
This remarkable outperformance is driven by the increasing global obesity epidemic - more than 2.5b adults globally are overweight, creating a surging demand for effective weight loss solutions. Tirzepatide and Wegovy have demonstrated profound efficacy in clinical trials, showcasing not only substantial weight loss but also improvements in cardiovascular health and diabetes markers. The dual benefits have expanded potential market beyond individuals seeking weight loss to include patients managing chronic conditions related to obesity.
Given the strong demand for effective weight loss solutions, combined with positive clinical outcomes and high-profile endorsements, tailwinds for the manufacturers of weight loss drugs to continue outperforming the broader market is well-founded.
Figure 1: Stellar outperformance by weight loss leaders
Source: LSEG, DBS
Download the PDF to read the full report which includes coverage on Credit, FX, Rates, and Thematics.
本資訊是由星展銀行集團公司（公司註冊號： 196800306E）（以下簡稱“星展銀行”）發佈僅供參考。其所依據的資訊或意見搜集自據信可靠之來源，但未經星展銀行、其關係企業、關聯公司及聯屬公司（統稱“星展集團”獨立核實，在法律允許的最大範圍內，星展集團針對本資訊的準確性、完整性、時效性或者正確性不作任何聲明或保證（含明示或暗示）。本資訊所含的意見和預期內容可能隨時更改，恕不另行通知。本資訊的發佈和散佈不構成也不意味著星展集團對資訊中出現的任何個人、實體、服務或產品表示任何形式的認可。以往的任何業績、推斷、預測或結果模擬並不必然代表任何投資或證券的未來或可能實現的業績。外匯交易蘊含風險。您應該瞭解外匯匯率的波動可能會給您帶來損失。必要或適當時，您應該徵求自己的獨立的財務、稅務或法律顧問的意見或進行此類獨立調查。
本資訊的發佈不是也不構成任何認購或達成任何交易之要約、推薦、邀請或招攬的一部分；在以下情況下，本資訊亦非邀請公眾認購或達成任何交易，也不允許向公眾提出認購或達成任何交易之要約，也不應被如此看待：例如在所在司法轄區或國家/地區，此類要約、推薦、邀請或招攬係未經授權；向目標物件進行此類要約、推薦、邀請或招攬係不合法；進行此類要約、推薦、邀請或招攬係違反法律法規；或在此類司法轄區或國家/地區星展集團需要滿足任何註冊規定。本資訊、資訊中描述或出現的服務或產品不專門用於或專門針對任何特定司法轄區的公眾。
本資訊是星展銀行的財產，受適用的相關智慧財產權法保護。本資訊不允許以任何方式（包括電子、印刷或者現在已知或以後開發的其他媒介）進行複製、傳輸、出售、散佈、出版、廣播、傳閱、修改、傳播或商業開發。
星展集團及其相關的董事、管理人員和/或員工可能對所提及證券擁有部位或其他利益，也可能進行交易，且可能向其中所提及的任何個人或實體提供或尋求提供經紀、投資銀行和其他銀行或金融服務。
在法律允許的最大範圍內，星展集團不對因任何依賴和/或使用本資訊（包括任何錯誤、遺漏或錯誤陳述、疏忽或其他問題）或進一步溝通產生的任何種類的任何損失或損害（包括直接、特殊、間接、後果性、附帶或利潤損失）承擔責任，即使星展集團已被告知存在損失可能性也是如此。
若散佈或使用本資訊違反任何司法轄區或國家/地區的法律或法規，則本資訊不得為任何人或實體在該司法轄區或國家/地區散佈或使用。本資訊由 (a) 星展銀行集團公司在新加坡；(b) 星展銀行（中國）有限公司在中國大陸；(c) 星展銀行（香港）有限責任公司在中國香港[DBS CY1] ；(d) 星展（台灣）商業銀行股份有限公司在台灣；(e) PT DBS Indonesia 在印尼；以及 (f) DBS Bank Ltd, Mumbai Branch 在印度散佈。
相關見解
- 美國大選增添匯市波動性22 Jul 2024
- 美國總統選舉對股市的影響22 Jul 2024
- Economics Weekly: Fed Easing on the Card19 Jul 2024
相關見解
- 美國大選增添匯市波動性22 Jul 2024
- 美國總統選舉對股市的影響22 Jul 2024
- Economics Weekly: Fed Easing on the Card19 Jul 2024